title: Increased production of platelet-derived thromboxane in patients with lupus anticoagulant.
abstract: The in vivo production of thromboxane A2 and prostacyclin was assessed in 31 samples from 25 patients with lupus anticoagulant and in 32 controls. The urinary excretion of 11-dehydro-thromboxane B2 (a major thromboxane metabolite of platelet origin) was very significantly increased (p less than 0.0003) in the patients contrasting with a lesser increase of urinary 2,3-dinor-6-keto-prostaglandin F1 alpha reflecting the vascular production of prostacyclin (p less than 0.02). Our study shows that in patients with lupus anticoagulant, platelet activation may occur without a compensatory increment in the vascular biosynthesis of prostacyclin suggesting an increased risk for thrombosis.
authors.affiliation: U150 INSERM, Hôpital Lariboisière, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Maclouf
authors.forename: F
authors.initials: F
authors.lastname: Lellouche
authors.forename: M
authors.initials: M
authors.lastname: Martinuzzo
authors.forename: P
authors.initials: P
authors.lastname: Said
authors.forename: L O
authors.initials: LO
authors.lastname: Carreras
mesh_terms: D000328:Adult; D001792:Blood Platelets / Q000378:metabolism*; D002855:Chromatography, Thin Layer; D015232:Dinoprostone / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000502:physiology*; D013931:Thromboxanes / Q000096:biosynthesis* / Q000097:blood
chemical_list: D016682:Lupus Coagulation Inhibitor; D013931:Thromboxanes; D015232:Dinoprostone